NCT05501704 - ETHAN - ET for Male BC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

April 1, 2026

Study Completion Date

April 1, 2036

Conditions

Male Breast CancerHormone Receptor-positive Breast CancerHormone Receptor Negative Breast Carcinoma

Interventions

DRUG

Tamoxifen

Taken orally

DRUG

Anastrozole

Taken orally

DRUG

Degarelix

Subcutaneous (under the skin) injection

DRUG

Abemaciclib

Taken orally

Trial Locations (7)

15232

RECRUITING

University of Pittsburgh Cancer Institute, Pittsburgh

19104

RECRUITING

University of Pennsylvania, Abramson Cancer Center, Philadelphia

20007

RECRUITING

Georgetown University Medical Center, Washington D.C.

27599

RECRUITING

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

55905

RECRUITING

Mayo Clinic, Rochester

02115

RECRUITING

Dana Farber Cancer Institute, Boston

77030-4009

RECRUITING

M. D. Anderson Cancer Center at University of Texas, Houston

All Listed Sponsors

collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Translational Breast Cancer Research Consortium (TBCRC)

UNKNOWN

lead

Jose Pablo Leone

OTHER